ClinicalTrials.gg
Not yet recruitingNCT07949682UNIRING-OBS SHUpdated Nov 19, 2026

Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock

An observational study in Septic Shock, Sepsis and Peripheral Arterial Disease (PAD), sponsored by POLYSAN Scientific & Technological Pharmaceutical Company. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by POLYSAN Scientific & Technological Pharmaceutical Company · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Study summary

Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock

02

Conditions studied

  • Septic Shock
  • Sepsis
  • Peripheral Arterial Disease (PAD)

Keywords

  • Capillary refill time
  • Microcirculation
  • Near-infrared spectroscopy
  • Vascular occlusion test
  • Reoxygenation slope
  • Hemodynamic coherence
  • PiCCO
  • Fluid therapy
  • Lactated Ringer's
  • Arginine sodium succinate
03

In context

Shock, Septic

1,082 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.

This study's planned enrollment of 60 is below the median of 110 across 407 observational studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

POLYSAN Scientific & Technological Pharmaceutical Company is the lead sponsor of 24 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults treated in participating intensive care units for urinary- or pulmonary/respiratory-source sepsis with current or recently documented septic shock, documented lower-extremity atherosclerotic peripheral artery disease, early hemodynamic stabilization, ongoing hypoperfusion, and PiCCO Plus already in place for clinical indications. Potentially eligible participants are screened consecutively during active recruitment periods.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Septic shock by Sepsis-3 currently or documented within the previous 24 hours.
  • Urinary or pulmonary/respiratory suspected or confirmed infection source.
  • Documented atherosclerotic disease of the lower-extremity arteries.
  • Mean arterial pressure at least 65 mm Hg with norepinephrine less than 0.2 micrograms/kg/min and no increase greater than 20 percent or new vasopressor during the previous 30 minutes.
  • PiCCO Plus already installed for clinical indications and technically usable.
  • At least one ongoing sign of hypoperfusion or microcirculatory dysfunction defined in the protocol.
  • Before any study-specific baseline procedure, the treating physician has independently decided that an additional crystalloid infusion is clinically indicated and has selected UNIFUZOL® or lactated Ringer's solution.
  • Thenar NIRS-VOT can be performed safely.
  • or another ethics-board-approved consent process is completed before study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  • Hemorrhagic, cardiogenic, or obstructive shock as the leading cause of instability.
  • Rapidly increasing vasopressor requirement or need for immediate hemodynamic rescue inconsistent with the protocol-defined stabilization phase.
  • fluid overload/pulmonary edema for which the treating physician considers additional fluid ; severe unstable ARDS.
  • Active major bleeding or another condition requiring urgent therapy that prevents standardized baseline assessment.
  • Expected survival less than 24 hours or limitation of intensive treatment.
  • Pregnancy or breastfeeding.
  • Participation in an interventional study expected to materially affect hemodynamics.
  • Contraindication to any component of the physician-selected fluid.
  • Upper-limb ischemia, severe Raynaud phenomenon, local thenar skin injury, or another condition making NIRS-VOT unsafe or uninterpretable.
  • Core temperature below 34 degrees Celsius.
  • Acute/critical lower-extremity ischemia requiring urgent vascular treatment or severely compromising peripheral assessments.
  • Unable to establish Tdecision/T0 or obtain pre-infusion baseline CRT; inability to obtain pre-infusion ReOx excludes the participant from the key NIRS analysis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • UNIFUZOL® exposure cohort

    Participants for whom the treating physician independently selected and actually started UNIFUZOL® at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids.

  • Lactated Ringer's exposure cohort

    Participants for whom the treating physician independently selected and actually started lactated Ringer's solution at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids.

06

What researchers measure

Primary outcomes

  1. Capillary Refill Time at 6 Hours

    Capillary refill time (CRT) in seconds measured using a standardized distal-finger technique. Two valid measurements are averaged; if they differ by more than 1.0 second, a third measurement is obtained and the median of three is used. The primary statistical comparison adjusts for strictly pre-infusion CRT and prespecified baseline covariates. Lower CRT is considered physiologically favorable.

    Time frame: 6 hours after start (window ±60 minutes)

Secondary outcomes

  1. Thenar NIRS Reoxygenation Slope at 6 Hours

    Post-occlusion reoxygenation slope (ReOx) derived from a standardized thenar near-infrared spectroscopy vascular occlusion test using a frozen common device/software/analysis algorithm. ReOx is analyzed continuously in percent StO2 per second and adjusted for pre-infusion ReOx. Higher ReOx is considered physiologically favorable.

    Time frame: 6 hours after start (window ±60 minutes)

  2. Sustained Macro-Microhemodynamic Coherent Response

    Protocol-defined supportive composite outcome. This measure is reported as a single binary value (Yes/No), which is considered achieved only if ALL of the following criteria are simultaneously met: full macrohemodynamic stability, peripheral/microvascular recovery, and pulmonary/volume safety at both 6 and 12 hours. The composite is not a validated diagnostic criterion and is analyzed as supportive/exploratory.

    Time frame: 6 and 12 hours after start

  3. Change in Capillary Refill Time Over 24 Hours

    Serial CRT at 60 minutes, approximately 2 hours/end of infusion, 6 hours, 12 hours, and 24 hours; analyses include continuous change and trajectory models.

    Time frame: From start through 24 hours

  4. Change in ReOx

    Serial ReOx from standardized NIRS-VOT.

    Time frame: From pre-infusion baseline through 24 hours

  5. Change in De-oxygenation slope

    DeOx from standardized NIRS-VOT (%/min).

    Time frame: From pre-infusion baseline through 24 hours

  6. Change in NIRS Vascular Reactivity Over 24 Hours (tissue oxygenation)

    Tissue oxygenation variables (%)

    Time frame: From pre-infusion baseline through 24 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 23 months later.

Of 202 observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Nov 19, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Nov 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949682
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Nov 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Alexey Kovalenko, Doc Biol Sci
Contact
science@polysan.ru
+78127108225 ext. 212
K.M. Lebedinsky
study chair · North-Western State Medical University named after I.I.Mechnikov
I. S. Simutis
principal investigator · Adult Intensive Care Unit, L.G. Sokolov North-Western District Scientific and Clinical Center, FMBA of Russia, St Petersburg, Russian Federation
A.Yu. Yakovlev
principal investigator · City Hospital No. 38 named after N.A. Semashko

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion